Treating Radiation‑related Nasopharyngeal Necrosis with Endostar in Patient with Nasopharyngeal Carcinoma: A Report of Two Cases and a Literature Review

Overview

Journal Mol Clin Oncol

Specialty Oncology

Date 2023 Jun 26

PMID 37359714

Authors

Jie Tang

Xiu-Wen Li

Yong Wu

Zhen Su

Yan He

Xue-Wen Sun

Xiao-Long Cao

Yi-Hua Li

Bi-Cheng Wang

Guo-Rong Zou

Affiliations

Soon will be listed here.

Abstract

Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN. However, clinical trials are required to confirm the results of the present study.

References

Han F, Zhao C, Huang S, Lu L, Huang Y, Deng X . Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2012; 24(8):569-76. DOI: 10.1016/j.clon.2011.11.010. View

Xu M, Zang J, Luo S, Wang J, Li X . Long-term survival outcomes and adverse effects of nasopharyngeal carcinoma patients treated with IMRT in a non-endemic region: a population-based retrospective study. BMJ Open. 2021; 11(8):e045417. PMC: 8330594. DOI: 10.1136/bmjopen-2020-045417. View

Liu J, Ning X, Sun X, Lu H, Gu Y, Wang D . Endoscopic sequestrectomy for skull base osteoradionecrosis in nasopharyngeal carcinoma patients: a 10‑year experience. Int J Clin Oncol. 2018; 24(3):248-255. DOI: 10.1007/s10147-018-1354-8. View

Wang X, Shi Y, Jia Y, Zhao W, Zhang L, Bai G . Tolerance and Pharmacokinetics of Recombinant Human Endostatin Administered as Single-Dose or Multiple-Dose Infusions in Patients With Advanced Solid Tumors: A Phase I Clinical Trial. Technol Cancer Res Treat. 2021; 20:15330338211064434. PMC: 8721376. DOI: 10.1177/15330338211064434. View

Zeng L, Tian Y, Sun X, Chen C, Han F, Xiao W . Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. Br J Cancer. 2013; 110(1):49-54. PMC: 3887308. DOI: 10.1038/bjc.2013.720. View

Han P, Wang X, Liang F, Liu Y, Qiu X, Xu Y . Osteoradionecrosis of the Skull Base in Nasopharyngeal Carcinoma: Incidence and Risk Factors. Int J Radiat Oncol Biol Phys. 2018; 102(3):552-555. DOI: 10.1016/j.ijrobp.2018.06.027. View

Zhang M, Li J, Shen G, Zou X, Xu J, Jiang R . Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015; 51(17):2587-95. DOI: 10.1016/j.ejca.2015.08.006. View

Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K . [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi. 2010; 8(4):283-90. DOI: 10.3779/j.issn.1009-3419.2005.04.07. View

Guan Y, Li A, Xiao W, Liu S, Chen B, Lu T . The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget. 2015; 6(32):33926-34. PMC: 4741813. DOI: 10.18632/oncotarget.5271. View

10.

Yang Q, Zou X, You R, Liu Y, Han Y, Zhang Y . Proposal for a new risk classification system for nasopharyngeal carcinoma patients with post-radiation nasopharyngeal necrosis. Oral Oncol. 2017; 67:83-88. DOI: 10.1016/j.oraloncology.2017.02.012. View

11.

Robard L, Louis M, Blanchard D, Babin E, Delanian S . Medical treatment of osteoradionecrosis of the mandible by PENTOCLO: preliminary results. Eur Ann Otorhinolaryngol Head Neck Dis. 2014; 131(6):333-338. DOI: 10.1016/j.anorl.2013.11.006. View

12.

Boehm T, Folkman J, Browder T, OReilly M . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390(6658):404-7. DOI: 10.1038/37126. View

13.

Bergers G, Javaherian K, Lo K, Folkman J, Hanahan D . Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999; 284(5415):808-12. DOI: 10.1126/science.284.5415.808. View

14.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

15.

Han B, Xiu Q, Wang H, Shen J, Gu A, Luo Y . [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)]. Zhonghua Zhong Liu Za Zhi. 2012; 33(11):854-9. View

16.

Lyons A, Ghazali N . Osteoradionecrosis of the jaws: current understanding of its pathophysiology and treatment. Br J Oral Maxillofac Surg. 2008; 46(8):653-60. DOI: 10.1016/j.bjoms.2008.04.006. View

17.

Chen M, Mai H, Sun R, Guo X, Zhao C, Hong M . Clinical findings and imaging features of 67 nasopharyngeal carcinoma patients with postradiation nasopharyngeal necrosis. Chin J Cancer. 2013; 32(10):533-8. PMC: 3845539. DOI: 10.5732/cjc.012.10252. View

18.

Luo J, Chia K, Chia S, Reilly M, Tan C, Ye W . Secular trends of nasopharyngeal carcinoma incidence in Singapore, Hong Kong and Los Angeles Chinese populations, 1973-1997. Eur J Epidemiol. 2007; 22(8):513-21. DOI: 10.1007/s10654-007-9148-8. View

19.

Eder Jr J, Supko J, Clark J, Puchalski T, Garcia-Carbonero R, Ryan D . Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002; 20(18):3772-84. DOI: 10.1200/JCO.2002.02.082. View

20.

Peng F, Xu Z, Wang J, Chen Y, Li Q, Zuo Y . Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 2012; 7(4):e34646. PMC: 3322143. DOI: 10.1371/journal.pone.0034646. View